Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Personalis's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Personalis's regulatory disclosures and financial reporting.
Tempus AI, Inc. has agreed to acquire Personalis, Inc., and senior leadership highlighted the announcement in LinkedIn posts by Tempus and its CEO. The communication primarily provides extensive forward-looking statements and legal disclosures related to the proposed merger.
It details numerous risks that could cause the merger not to close or to differ from expectations, including failure to obtain Personalis stockholder approval, failure or delay in securing required governmental and regulatory clearances, potential litigation, higher-than-expected costs, integration challenges, reimbursement and regulatory uncertainties, and risks tied to the combined company’s use of artificial intelligence. It also notes that Personalis may have a right to terminate the merger agreement if Tempus’ Class A common stock price falls below $46.00 prior to closing.
The communication clarifies that it is not an offer or solicitation to buy or sell securities and explains that Tempus intends to file a registration statement on Form S-4, including a proxy statement/prospectus for Personalis stockholders, and that Tempus, Personalis and affiliates will file a Schedule 13E-3. Investors are urged to read the S-4, proxy statement/prospectus and Schedule 13E-3, when available, and are directed to the SEC and each company’s investor relations website for free copies. It also notes that directors and executive officers of both companies may be deemed participants in the proxy solicitation, with their security holdings described in prior Form 10-Ks, proxy statements and Forms 3, 4 and 5.
Tempus AI, Inc. plans to acquire all outstanding shares of Personalis, Inc. it does not already own for $16.25 per share, a 6% premium to Personalis’ July 17, 2026 close and a 28% premium to its unaffected 30-day VWAP. The agreement implies a total transaction value of $1.7 billion, or $1.5 billion net of Tempus’ existing ownership. Consideration will be a mix of Tempus stock and up to 50% cash at Tempus’s discretion, with Personalis holders receiving a floating exchange ratio of Tempus common stock per Personalis share, capped at 0.3356x. Closing is targeted for the fourth quarter of 2026 at the earliest, subject to Personalis shareholder approval, regulatory clearances and customary conditions.
Strategically, Tempus aims to more tightly integrate Personalis’ ultrasensitive molecular residual disease (MRD) technology, NeXT Personal Dx, into its AI-enabled precision oncology platform, addressing a U.S. MRD total addressable market of over $20 billion with currently low penetration. Personalis has delivered over 35,000 molecular tests, and MRD testing volumes grew 33% sequentially in the latest quarter to 10,384 tests, supporting Tempus’s expectations for revenue growth, richer longitudinal data and deeper biopharma partnerships.
Tempus AI, Inc. agreed to acquire Personalis, Inc. through a two-step merger in which Personalis will first merge into a Tempus subsidiary and then into a second Tempus subsidiary, becoming a wholly owned subsidiary of Tempus. At closing, each share of Personalis common stock (excluding cancelled and dissenting shares) will be converted into merger consideration primarily in Tempus Class A common stock based on an exchange ratio tied to the 15-day volume-weighted average price of Tempus shares before closing. Tempus may elect to pay cash for up to 50% of Personalis shares, while keeping at least 40% of total stockholder consideration in Tempus stock to support tax-free reorganization treatment under Section 368(a) of the Code.
Closing is subject to approval by Personalis stockholders, effectiveness of a Form S-4 registration statement, Nasdaq listing of Tempus shares issued in the merger, expiration or termination of Hart-Scott-Rodino and other antitrust waiting periods, tax opinions on reorganization status, and absence of material adverse effects for either party. Personalis is bound by no-shop covenants but may consider a Superior Proposal, subject to notice and matching rights and a termination fee. Either side may owe the other a termination or reverse termination fee of approximately $76.8 million in specified circumstances, including certain regulatory blocks or adverse board recommendation changes. Personalis may also terminate if Tempus’ stock price falls below $46.00 shortly before the scheduled closing, and the outside date to complete the deal is April 20, 2027, with potential automatic extensions for regulatory delays.
Personalis, Inc. agreed to be acquired by Tempus AI, Inc. in a two-step merger that will make Personalis a wholly owned subsidiary of Tempus. Personalis stockholders will receive $16.25 per share, implying about $1.5 billion enterprise value net of Tempus’ existing stake, a 6% premium to the prior Friday close and 28% to the unaffected 30‑day VWAP. Consideration is a 100% stock deal, with Tempus able to elect cash for up to half of the total; Personalis holders will receive a floating Tempus share exchange ratio capped at 0.3356 per Personalis share. Closing is targeted for late 2026 or early 2027, subject to Personalis stockholder and regulatory approvals and other conditions, including a provision allowing Personalis to terminate if Tempus’ Class A stock trades below $46.00. Personalis also reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% quarter‑over‑quarter volume increase, highlighting growth in its minimal residual disease business within an estimated $20 billion MRD market.
Personalis, Inc. agreed to be acquired by Tempus AI, Inc. under a definitive merger agreement announced on July 20, 2026. Personalis shareholders are expected to receive $16.25 per share, implying an enterprise value of $1.5 billion net of Tempus’s existing ownership, in a transaction structured as stock with up to half of the consideration potentially payable in cash at Tempus’s discretion. The deal represents a 6% premium to the prior Friday close and a 28% premium to the unaffected 30‑day volume-weighted average price.
The combination is intended to integrate Personalis’ tumor-informed minimal residual disease technology with Tempus’s AI-enabled precision oncology and multimodal data platform, targeting what the companies describe as a $20 billion MRD market opportunity. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder approval, regulatory approvals and other customary conditions, including a Tempus share-price condition. Personalis also reported preliminary Q2 revenue of $22.4 million and delivery of 10,384 clinical tests, a 33% quarter‑over‑quarter increase in test volumes.
Personalis, Inc. President and CMO Richard Chen reported an exercise-and-sale transaction in the company’s common stock. He exercised stock options for 100,000 shares at an exercise price of $2.44 per share and sold 100,000 shares in open-market transactions at a weighted average price of $15.15 per share, within a price range of $15.01 to $15.45 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, Chen holds 173,880 shares of Personalis common stock directly, and the exercised option grant is fully used.
Personalis, Inc. director and Chief Executive Officer Christopher M. Hall reported paired option exercises and share sales in company stock. He exercised options to acquire 100,000 shares of common stock at an exercise price of $1.61 per share and sold 100,000 shares of common stock in open-market transactions at a weighted average price of $15.08 per share, with sale prices ranging from $15.00 to $15.24. The filing notes that these transactions were effected pursuant to a pre-arranged Rule 10b5-1 trading plan. One transaction entry shows Hall holding 235,986 shares directly after the reported sale, while another shows 335,986 shares directly after the related option exercise.
Morgan Stanley Smith Barney LLC filed a notice under Rule 144 proposing the sale of 100,000 shares of Common Stock on 07/09/2026 following the exercise of stock options for cash. The filing lists an aggregate value of $1,411,000.00.
The filing also discloses recent Rule 10b5-1 sales by Christopher Hall: 100,000 shares on 06/26/2026 (proceeds $1,314,580), 80,091 shares on 05/29/2026 (proceeds $882,843.09), and 19,909 shares on 05/28/2026 (proceeds $219,319.42).
Personalis, Inc. executive Aaron Tachibana, the company’s CFO and COO, reported an exercise-and-sell transaction in company stock. He exercised stock options covering 4,982 shares of common stock at an exercise price of $5.32 per share, then sold 4,982 shares of common stock in an open-market sale at $14.00 per share. According to the disclosure, these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, which means the timing was set in advance. After the transactions, Tachibana directly held 198,833 shares of Personalis common stock.